Iasibon

Ibandronic Acid, the active ingredient in Iasibon, is a bisphosphonate presented as an intravenous solution for intravenous use. It treats postmenopausal osteoporosis, Paget's disease of bone, and bone metastases. GNH USA supplies Iasibon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Iasibon (ibandronic acid) is a bisphosphonate that reduces bone resorption in several skeletal disorders.

Osteoporosis (postmenopausal): improves bone mineral density and lowers fracture risk. Paget's disease of bone: normalizes bone turnover and alleviates disease activity. Bone metastases: helps prevent skeletal‑related events and reduces bone pain.

Common Side Effects: - Flu‑like symptoms such as fever and chills. - Musculoskeletal pain or joint discomfort. - Nausea or mild gastrointestinal upset. - Transient low calcium levels.

Serious or Rare Side Effects: - Acute renal failure or significant decline in kidney function. - Osteonecrosis of the jaw, especially after dental procedures. - Severe hypocalcemia requiring medical intervention. - Anaphylactic or severe allergic reactions.

Iasibon requires careful monitoring and patient education before administration. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Calcium and vitamin D: ensure adequate supplementation to reduce hypocalcemia risk. - Pregnancy: avoid use; safety category is unknown and risks cannot be excluded. - Concomitant nephrotoxic drugs: use with caution when patients receive other renal‑affecting agents. - Cardiac monitoring: be aware of reports of atrial fibrillation in some patients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Iasibon may interact with several medicines; clinical judgment is required.

Major Interactions (Avoid): - Other bisphosphonates: increased risk of renal toxicity. - Concomitant IV aminoglycosides: additive nephrotoxic potential. - High‑dose NSAIDs: may exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Calcium or multivitamin supplements given within 24 h of infusion: may reduce drug binding. - Antacids containing aluminum or magnesium: can interfere with drug activity. - Warfarin: possible alteration of INR; monitor coagulation parameters.